- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Giora Sharf Discusses Ways to Represent the CML Patient Voice
There are many ways patients with chronic myelogenous leukemia can ensure they are active participants in their own treatment, according to Giora Sharf, co-founder of the CML Advocates Network.
Becoming active participants in their own care by understanding treatments and becoming a full partner with their physicians is not the extent to which patients with chronic myelogenous leukemia (CML) can make sure their voices are heard, Giora Sharf, co-founder of the CML Advocates Network, said at the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, California.
In addition to empowering patients by educating them with materials like patient-friendly guidelines to CML treatment, his network is partnered with companies and researchers so the patient voice can be heard during the research and development process and they can be represented throughout the entire process.
Drug Interactions With Ibrutinib Common, Linked to Higher Infection Risk in CLL
September 16th 2025Drug interactions with ibrutinib may not shorten survival when managed carefully, though the significant increase in infection-related hospitalizations tied to CYP3A inhibitors signals an urgent need for closer monitoring, dose adjustment, and proactive infection prevention strategies.
Read More
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
